REFERENCES

• BoldenC.CusackB.RichelsonE.Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther.19925765801346637
   PubMed Web of Science ®Google Scholar
• YamamuraHI.SnyderSH.Muscarinic cholinergic receptor binding in the longitudinal muscle of the guinea pig ileum with [3H]quinuclidinyl benzilate. Mol Pharmacol.197410861867
   Web of Science ®Google Scholar
• GaussCJ.Geburten in kunstlichem Dâmmerschlaf. Arch Gynaekol.190678579631
   Google Scholar
• BartusRT.DeanRL.PontecorvoMJ.FlickerC.The cholinergic hypothesis: a historical overview, current perspective, and future directions.Ann N Y Acad Sci.19854443323582990293
   PubMed Web of Science ®Google Scholar
• PopeA.HessHH.LewinE.Microchemical pathology of the cerebral cortex in pre-senile dementias. Trans Am Neurol Assoc.19658915165828492
   PubMedGoogle Scholar
• DrachmanDA.LeavittJ.Human memory and the cholinergic system: a relationship to aging? Arch Neurol.1974301131214359364
   PubMed Web of Science ®Google Scholar
• BowenDM.SmithCB.WhiteP.DavisonAN.Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain.19769945949611871
   PubMed Web of Science ®Google Scholar
• DaviesP.MaloneyAJF.Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet.19762140363862
   PubMed Web of Science ®Google Scholar
• PerryEK.PerryRH.BlessedG.TomlinsonBE.Necropsy evidence of central cholinergic deficits in senile dementia. Lancet.1977118964712
   PubMed Web of Science ®Google Scholar
• PerryEK.TomlinsonBE.BlessedG.BergmannK.GibsonPH.PerryRH.Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ.1978214571459719462
   PubMed Web of Science ®Google Scholar
• MountjoyCQ.RossorMN.IversenLL.RothM.Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain.19841075075186722514
   PubMed Web of Science ®Google Scholar
• WhitehousePJ.PriceDL.ClarkAW.CoyleJT.DeLongMR.Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol.1981101221267283399
   PubMed Web of Science ®Google Scholar
• NakanoI.HiranoA.Loss of large neurons in the medial septal nucleus in an autopsy case of Alzheimer's disease. J Neuropathol Exp Neurol.198241341
   Web of Science ®Google Scholar
• MesulamMM.MufsonEJ.LeveyAI.WainerBH.Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol.19832141701976841683
   PubMed Web of Science ®Google Scholar
• EverittBJ.SirkiàTE.RobertsAC.JonesGH.RobbinsTW.Distribution and some projections of cholinergic neurons in the brain of the common marmoset, Callithrix jacchus. J Comp Neurol.1988271533558
   PubMed Web of Science ®Google Scholar
• AlonsoJR.UHS.AmaralDG.Cholinergic innervation of the primate hippocampal formation. II. Effects of fimbria/fornix transection. J Comp Neurol.19963755275518930785
   PubMed Web of Science ®Google Scholar
• BartusRT.DeanRL.FisherSK.Cholinergic treatment for age-related memory disturbances: dead or barely coming of age? In: Crook, T, Bartus R, Ferris S, Gershon S, eds. Treatment Development Strategies for Alzheimer's Disease. Madison, Wis: Mark Powley Associates1986421450
   Google Scholar
• HaganJJ.The status of the cholinergic hypothesis of dementia. In: Nicholson D, ed. Anti-dementia Agents. Research and Prospects for Therapy. London, UK: Academic Press199485138
   Google Scholar
• SalterM.BrunoJP.HimmelheberAM.Cortical acetylcholine and attention: neuropharmacological and cognitive principles directing treatment strategies for cognitive disorders. In: Brioni JD, Decker MW, eds. Pharmacological Treatments of Alzheimer's Disease: Molecular and Neurobiological Foundations. New York, NY: Wiley-Liss1997105128
   Google Scholar
• FrancisPT.PalmerAM.SnapeM.WilcockGK.The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry.19996613714710071091
   PubMed Web of Science ®Google Scholar
• LydonRG.Cholinergic neurons and memory: an historical perspective and overview of current research. In: Stone TW, ed. CMS Neurotransmitters and Neuromodulators: Acetylcholine. London, UK: CRC Press1995197232
   Google Scholar
• RichardsonJS.MillerPS.LemayJS.et al.Mental dysfunction and the blockade of muscarinic receptors in the brain of the normal elderly.Prog Neuropsychopharmacol Biol Psychiatry.198596516544089189
   PubMed Web of Science ®Google Scholar
• SunderlandT.TariotP.MurphyDL.WeingartnerH.MuellerEA.CohenRM.Scopolamine challenges in Alzheimer's disease. Psychopharmacology.1985872472493931154
   PubMed Web of Science ®Google Scholar
• SunderlandT.TariotPN.MuellerEA.MurphyDL.WeingartnerH.CohenRM.Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. Psychopharmacol Bull.1985216766793898182
   PubMedGoogle Scholar
• SunderlandT.TariotPN.CohenRM.WeingartnerH.MuellerEA.MurphyDL.Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry1987444184263579494
   PubMed Web of Science ®Google Scholar
• SunderlandT.TariotPN.NewhousePA.Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatrie populations. Brain Res.19884723713893066441
   PubMedGoogle Scholar
• ZemishlanyZ.ThomeAE.Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. IsrJ Psychiatry Relat Sci.19912832411800456
   PubMed Web of Science ®Google Scholar
• FlickerC.FerrisSH.SerbyM.Hypersensitivity to scopolamine in the elderly. Psychopharmacology.19921074374411615141
   PubMed Web of Science ®Google Scholar
• GitelmanDR.ProhovnikI.Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging.1992133133181522945
   PubMed Web of Science ®Google Scholar
• RayPG.MeadorKJ.loringDW.ZamriniEW.YangXH.BuccafuscoJJ.Central cholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol.1992572771317178
   PubMedGoogle Scholar
• MolchanSE.MartinezRA.HillJL.et al.Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev.1992172152261467811
   PubMedGoogle Scholar
• RabeyJM.NeufeldMY.TrevesTA.SifrisP.KorczynAD.Cognitive effects of scopolamine in dementia. J Neural Transm Gen Sect1996103873881
   PubMed Web of Science ®Google Scholar
• TariotPN.PatelSV.HendersonRE.Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology199612550568724448
   PubMed Web of Science ®Google Scholar
• BarkerA.JonesR.PriorJ.WesnesK.Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up. Int J Geriat Psychiatry.199813244247
   PubMed Web of Science ®Google Scholar
• GhoneimMM.MewaldtSP.Studies on human memory: the interactions of diazepam, scopolamine and physostigmine. Psychopharmacology.19775216403551
   PubMed Web of Science ®Google Scholar
• AnismanH.Time-dependent changes in activity, reactivity, and responsivity during shock: effects of cholinergic and catecholaminergic manipulations. Neurology.197727783790560649
   PubMedGoogle Scholar
• LiljequistR.MattilaMJ.Effect of physostigmine and scopolamine on the memory functions of chess players. Med Biol.19795742405
   Google Scholar
• MewaldtSP.GhoneimMM.The effects and interactions of scopolamine and methamphetamine on human memory. Pharmacol Biochem Behav.197910205210450929
   PubMed Web of Science ®Google Scholar
• PrestonGC.WardC.LinesCR.PoppletonP.HaighJR.TraubM.Scopolamine and benzodiazepine models of dementia: cross reversals by RO 151788 and physostigmine. Psychopharmacology.1989984874942570433
   PubMed Web of Science ®Google Scholar
• WesnesKA.SimpsonPM.WhiteL.et al.Cholinesterase inhibition in the scopolamine model of dementia. Ann N Y Acad Sci.1991 6402682711776749
   PubMed Web of Science ®Google Scholar
• MohsRC.DavisKL.Interaction of choline and scopolamine in human memory. Life Sci.1985371931974010475
   PubMed Web of Science ®Google Scholar
• WesnesKA.SimpsonPM.ChristmasL.AnandR.McClellandGR.The effects of moclobemide on cognition. J Neural Transm.198928(suppl)91102
   Google Scholar
• WesnesK.AnandR.LorscheidT.Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand.1990360(suppl)7172
   Google Scholar
• PatatA.KleinMJ.SurjusA.HucherM.GranierJ.RU 41656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. Eur J Clin Pharmacol.1991412252311684155
   PubMed Web of Science ®Google Scholar
• CanalN.FranceschiM.AlberoniM.CastiglioniC.De MolinerP.LongoniA.Effect of L-alpha-glycerylphosphorylcholine on amnesia caused by scopolamine. IntJ Clin Pharmacol Ther Toxicol.1991291031072071257
   PubMedGoogle Scholar
• PredaL.AlberoniM.BressiS.et al.Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology.19931104214267870912
   PubMed Web of Science ®Google Scholar
• WesnesK.AnandR.SimpsonP.ChristmasL.The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Int J Geriatr Psychiatry.1990695102
   Google Scholar
• WesnesK.SimpsonPM.KiddAG.The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Med Sci Res.19871510631064
   Google Scholar
• ShrotriyaR.StalloneF.RobinsonD.BradyM.TempleD.Clinical pharmacology of BMY 21 502 - a potential cognitive enhancer. Abstracts of the 17th CINP, Kyoto, Japan 1990 9 10-14 Vol II 230
   Google Scholar
• JonesRW.WesnesKA.KirbyJ.Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci.19916402412441837979
   PubMed Web of Science ®Google Scholar
• BrassEP.PolinskyR.SramekJJ.et al.Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol.19951558627714229
   PubMed Web of Science ®Google Scholar
• DukaT.OttH.RohloffA.VoetB.The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology.19961233613738867876
   PubMed Web of Science ®Google Scholar
• GroberE.GitlinHL.BangS.BuschkeH.Implicit and explicit memory in young, old, and demented adults. J Clin Exp Neuropsychol.1992142983161572951
   PubMed Web of Science ®Google Scholar
• DanionJM.ZimmermannMA.Willard-SchroederD.et al.Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers. Psychopharmacology.19901024224242251340
   PubMed Web of Science ®Google Scholar
• BishopKl.CurranHV.An investigation of the effects of benzodiazepine receptor ligands and of scopolamine on conceptual priming. Psychopharmacology.19981403453539877014
   PubMed Web of Science ®Google Scholar
• RustedJM.Eaton-WilliamsP.WarburtonDM.A comparison of the effects of scopolamine and diazepam on working memory. Psychopharmacology.19911054424451798839
   PubMed Web of Science ®Google Scholar
• LydonRG.NakajimaS.Differential effects of scopolamine on working and reference memory depend upon level of training. Pharmacol Biochem Behav.1992436456601438505
   PubMed Web of Science ®Google Scholar
• LiHB.MatsumotoK.TohdaM.YamamotoM.WatanabeH.NMDA antagonists potentiate scopolamine-induced amnestic effect. Behav Brain Res.1997832252289062690
   PubMed Web of Science ®Google Scholar
• DunneMP.Scopolamine and sustained retrieval from semantic memory. J Psychopharmacol.199041318
   PubMedGoogle Scholar
• EustacheF.AgnielA.Neuropsychologie clinique des démences: évaluation et prise en charge. Marseille, France: Solal1995
   Google Scholar
• FleischmanDA.GabrieliJDE.RemingerSL.VaidyaCJ.BennettDA.Object decision priming in Alzheimer's disease. J int Neuropsychol Soc.199844354469745233
   PubMed Web of Science ®Google Scholar
• ChristensenH.GriffithsK.MackinnonA.JacombP.A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int Neuropsychol Soc.199736316519448376
   PubMedGoogle Scholar
• ErgisAM.Van der LindenM.DeweerB.Explicit memory, procedural learning and lexical priming in Alzheimer's disease. Cortex.1994301131268004981
   PubMed Web of Science ®Google Scholar
• EbertU.KirchW.Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin invest.1998289449499824440
   PubMed Web of Science ®Google Scholar
• GrasbyPM.FrithCD.PaulesuE.FristonKJ.FrackowiakRS.DolanRJ.The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. Exp Brain Res.19951043373487672026
   PubMed Web of Science ®Google Scholar
• CohenRM.GrossM.SempleWE.NordahlTE.SunderlandT.The metabolic brain pattern of young subjects given scopolamine. Exp Brain Res.19941001331437813641
   PubMed Web of Science ®Google Scholar
• BlinJ.PierceyMF.GiuffraME.MouradianMM.Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography J Neurol Sci.1994 12344518064320
   PubMed Web of Science ®Google Scholar
• MolchanSE.MatochikJA.ZametkinAJ.et al.A double FDG/PET study of the effects of scopolamine in older adults. Neuropsychopharmacology.1994101911987916916
   PubMed Web of Science ®Google Scholar
• SunderlandT.EspositoG.MolchanSE.CoppolaR.Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology.19951212312418545529
   PubMed Web of Science ®Google Scholar
• AnisNA.BerrySC.BurtonNR.LodgeD.The dissociative anesthetics, ketamine and phencyclidine, selectively decrease excitation of central neurons by N-methyl-D-aspartate. Br J Pharmacol.198383179185
   Google Scholar
• YamakuraT.MoriH.MasakiH.ShimojiK.MoshinaM.Differential sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport.199346876908347808
   PubMedGoogle Scholar
• KornbuberJ.WiltfangJ.The role of glutamate in dementia. J Neural Transm.199853(suppl)277287
   Google Scholar
• PerlTM.BedardL.KosatskyT.HockinJC.ToddECD.RemisRS.An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med.1990322177517801971709
   PubMed Web of Science ®Google Scholar
• MasliahE.AlfordM.DeTeresaR.MalloryM.HansenL.Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol.1996407597668957017
   PubMed Web of Science ®Google Scholar
• LiS.MalloryM.AlfordM.TanakaS.MasliahE.Glutamate transporteralterations in Alzheimer's disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol.1997569019119258260
   PubMed Web of Science ®Google Scholar
• TekinS.Aykut-BingôlC.TanridagT.AktanS.Antiglutamatergic therapy in Alzheimer's disease-effects of lamotrigine. J Neural Transm.19981052953039660108
   PubMed Web of Science ®Google Scholar
• PanegyresPK.The effects of excitotoxicity on the expression of the amyloid precursor protein gene in the brain and its modulation by neuroprotective agents. J Neural Transm.19981054634789720974
   PubMed Web of Science ®Google Scholar
• GôrtelmeyerR.ErblerH.Memantine in the treatment of mild-to-moderate dementia syndrome. A double-blind placebo-controlled study. Drug Res.199242904913
   PubMed Web of Science ®Google Scholar
• TanakaS.LiuL.KimuraJ.et al.Age-related changes in the proportion of amyloid precursor protein mRNAs in Alzheimer's disease and other neurological disorders. Brain Res Mol Brain Res.1992153033101331685
   PubMedGoogle Scholar
• JohnsonSA.McNeillT.CordellB.FinchCE.Relation of neuronal APP751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease. Science.199028548572111579
   PubMedGoogle Scholar
• MattsonMP.ChengB.DavisD.BryantK.LieberburgI.RydelRE.β-Amy-loid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci.1992123763891346802
   PubMed Web of Science ®Google Scholar
• KlegerisA.McGeerPL.Beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res.1997492292359272645
   PubMed Web of Science ®Google Scholar
• EsclaireF.LesortM.BlanchardC.HugonJ.Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res.1997493093189260742
   PubMed Web of Science ®Google Scholar
• De BoniU.McLachlanDRC.Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons, by glutamate and aspartate. J Neurol Sci.1985681051182861254
   PubMed Web of Science ®Google Scholar
• HarrisJA.BiersnerRJ.EdwardsD.BaileyLW.Attention, learning, and personality during ketamine emergence: a pilot study. Anesth Analg.1975541691721092205
   PubMed Web of Science ®Google Scholar
• PanditSK.KotharySP.KumarS.Low dose intravenous infusion technique with ketamine. Anesthesia.198035669675
   PubMed Web of Science ®Google Scholar
• GhoneimMM.HinrichsJV.MewaldtSP.PetersenRC.Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol.1985570773988972
   PubMed Web of Science ®Google Scholar
• OyeI.PaulsenO.MaursetA.Effects of ketamine on sensory perception: evidence for a role of W-methyl-D-aspartate receptors. J Pharmacol Exp Ther.1992260120912131312163
   PubMed Web of Science ®Google Scholar
• KrystalJH.KarperLP.SeibylJP.et al.Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry.1994511992148122957
   PubMed Web of Science ®Google Scholar
• KrystalJH.KarperLP.BennetA.et al.Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology.19981352132299498724
   PubMed Web of Science ®Google Scholar
• KrystalJH.D'SouzaDC.KarperLP.et al.Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology.199914519320410463321
   PubMed Web of Science ®Google Scholar
• MalhotraAK.FinalsDA.WeingartnerH.et al.NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology.1996 143013078703299
   PubMed Web of Science ®Google Scholar
• AdlerCM.GoldbergTE.MalhotraAK.PickarD.BreierA.Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry.1998438118169611670
   PubMed Web of Science ®Google Scholar
• NewcomerJW.FarberNB.Jevtovic-TodorovicV.et al.Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology.1999201061189885791
   PubMed Web of Science ®Google Scholar
• SunderlandT.MolchanSE.LittleJT.BahroM.PutnamKT.WeingartnerH.Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans. Alzheimer Dis Assoc Disord.199711(suppl 4)S23S269339269
   PubMed Web of Science ®Google Scholar
• LittleJT.JohnsonDN.MinichielloM.WeingartnerH.SunderlandT.Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral and physiologic responses. Neuropsychopharmacology.19981960699608577
   PubMed Web of Science ®Google Scholar
• BroocksA.LittleJT.MartinA.et al.The influence of ondansetron and mchlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biol Psychiatry.1998434084169532345
   PubMed Web of Science ®Google Scholar
• VitielloB.MartinA.HillJ.et al.Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology.19971615248981385
   PubMed Web of Science ®Google Scholar
• Gomez-lslaT.HymanBT.Connection and cognitive impairment in Alzheimer's disease. In: Hyman BT, Duyckaerts C, Christen Y, eds. Connections, Cognition and Alzheimer's Disease (Research and Perspectives in Alzheimer's Disease). Berlin, Germany: Springer-Verlag1997149166
   Google Scholar
• LadnerCJ.LeeJM.Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol.1998577197319720487
   PubMed Web of Science ®Google Scholar
• AuldDS.KarS.QuirionR.P-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci.19982143499464686
   PubMed Web of Science ®Google Scholar
• YoshikawaK.Neurotoxicity of amyloid p-protein and the amyloid pprotein precursor. In: Goate A, Ashall F, eds. Pathobiology of Alzheimer's Disease. London, UK: Academic Press1995145165
   Google Scholar
• KarS.SetoD.GaudreauP.QuirionR.p-Amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal formation. J Neurosci.199616103410408558231
   PubMed Web of Science ®Google Scholar
• KarS.IssaAM.SetoD.AuldDS.CollierB.QuirionR.Amyloid p-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J, Neurochem.199870217921879572306
   PubMed Web of Science ®Google Scholar
• PedersenWA.KloczewiakMA.BlusztajnJK.Amyloid beta protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA.199693806880718755604
   PubMed Web of Science ®Google Scholar
• HoshiM.TakashimaA.MuramayaM.et al.Non-toxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem.1997272203820418999897
   PubMed Web of Science ®Google Scholar
• SheuKFR.KimYT.BlassJP.WekslerME.An immunohistochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann Neurol.1985174444494004169
   PubMed Web of Science ®Google Scholar
• MaireJCE.WurtmanRJ.Choline production from choline-containing phospholipids: a hypothetical role in Alzheimer's disease and aging. Prog Neuropsychopharmacol Biol Psychiatry198486376426543397
   PubMed Web of Science ®Google Scholar
• PaviaJ.de CeballosML.de la CuestaFS.Alzheimer's disease: relationship between muscarinic cholinergic receptors, p-amyloid and tau proteins. Fundam Clin Pharmacol.1998124734819794144
   PubMed Web of Science ®Google Scholar
• WhitehousePJ.MartinoAM.MarcusKA.et al.Reductions in acetylcholine and nicotinic binding in several degenerative diseases. Ann Neurol.198845722724
   Google Scholar
• NordbergA.AlafuzoffI.WindbladB.Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res.1992311031111613816
   PubMed Web of Science ®Google Scholar
• BuxbaumJD.OishiM.ChenHI.et al.Cholinergic agonists and interleukin-1 regulate processing and secretion of Alzheimer β4 amyloid protein precursor. Proc Natl Acad Sci U S A.19928910075100781359534
   PubMed Web of Science ®Google Scholar
• NitschRM.SlackBE.WurtmanRJ.GordonJH.Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science.19922583043071411529
   PubMed Web of Science ®Google Scholar
• GreenwoodAF.PowersRE.JopeRS.Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience.1995691251388637611
   PubMed Web of Science ®Google Scholar
• JopeRS.SongL.PowerRE.Cholinergic activation of phosphoinositide signalling is impaired in Alzheimer's disease brain. Neurobiol Aging.1997181111208983039
   PubMed Web of Science ®Google Scholar
• FlynnDD.WeinsteinDA.MashDC.Loss of high-affinity agonist binding to M, muscarinic receptors in Alzheimer's disease: implication for the failure of cholinergic replacement therapies. Ann Neurol.1991292562622042942
   PubMed Web of Science ®Google Scholar
• KellyJF.FurukawaK.BargerSW.et al.Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci U SA.19969367536758
   PubMed Web of Science ®Google Scholar
• QianN.RussellM.JohnsonGL.Acetylcholine muscarinic receptor regulation of the Ras/Raf/MAP kinase pathway. Life Sci.19955694594910188797
   PubMed Web of Science ®Google Scholar
• SadotE.GurwitzD.BargJ.BeharL.GinzburgI.FisherA.Activation of m, muscarinic acetylcholine receptor regulates the tau phosphorylation in transfected PC12 cells. J Neurochem.1996668778808592166
   PubMed Web of Science ®Google Scholar
• SchliebsR.RessnerS.Distribution of muscarinic acetylcholine receptors in the CNS. In: Stone TW, ed. CMS Neurotransmitters and Neuromodulators: Acetylcholine. London, UK: CRC Press19956783
   Google Scholar
• MoriyaH.TakagiY.NakanishiT.HayashiM.TaniT.HirotsuI.Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (MACHR) subtypes and MACHRS in rat heart and submandibular gland. Life Sci.1999642351235810374898
   PubMed Web of Science ®Google Scholar
• JaupBH.BlomstrandC.Cerebrospinal fluid concentrations of pirenzepine after therapeutic dosage. ScandJ Gastroenterol.198015(suppl 66)3537
   Web of Science ®Google Scholar
• StacherG.BauerP.SchmiererG.SteinringerH.The effect of intramuscular pirenzepine on oesophageal contractile activity and lower oesophageal sphincter pressure under fasting conditions and after a standard meal. A double-blind study. IntJ Clin Pharmacol Biopharm.197917442448511419
   PubMedGoogle Scholar
• FinkM.IrwinP.EEG and behavioral effects of pirenzepine in normal volunteers. Scand J Gastroenterol.198066(suppl)3946
   Google Scholar
• WaltersL.BartelP.SommersDK.BeckerP.The effects of anticholinergics on the photopalpebral reflex, memory and mood. Methods Find Exp Clin Pharmacol.1988104194253419245
   PubMedGoogle Scholar
• MooreCL.WolfeM.Inhibition of p-amyloid formation as a therapeutic strategy. Exp Opin Ther Patents.19999135146
   Web of Science ®Google Scholar
• SotoC.Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today.1999534335010431167
   PubMedGoogle Scholar
• SchenkD.BarbourR.DunnW.et al.Immunization with amyloid-p attenuates Alzheimer-disease-like pathology in the PDAPP mouse.Nature.199940017317710408445
   PubMed Web of Science ®Google Scholar
• MolchanSE.MellowAM.LawlorBA.et al.TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology.199010084892104988
   PubMed Web of Science ®Google Scholar
• GibbsRB.BurkeAM.JohnsonDA.Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention. Horm Behav.1998341121259799622
   PubMed Web of Science ®Google Scholar
• SilvaRH.FelicioLF.Frussa-FilhoR.Ganglioside GM1 attenuates scopolamine-induced amnesia in rats and mice. Psychopharmacology.19991411111179952034
   PubMed Web of Science ®Google Scholar
• EglenRM.ChoppinA.DillonMP.HegdeS.Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol.1999342643210419852
   PubMed Web of Science ®Google Scholar